After falling 17 per cent since the start of the year to its March lows, the stock of the country’s largest pharmaceutical ...

Deal-making news last week included US drug developer KalVista Pharma signing a licensing agreement with Kaken Pharma to market its investigational hereditary angioedema (HAE) drug sebetralstat in ...

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...

Indian drugmaker Sun (BSE: 524715) shares were buzzing in trade on the last trading day of the week to April 11, rising as ...

The US Court of Appeals for the Federal Circuit vacated a preliminary injunction on Leqselvi’s launch, lifting restrictions ...

According to market estimates, Leqselvi is projected to contribute $90 million to Sun Pharma's sales in FY26, and $125 ...

Emkay Global Financial is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 2400 in its ...

Emkay Global Financial Services, in a client note, described the development as “materially positive,” as it removes a key ...

Emkay Global maintains a 'Buy' rating on Sun Pharma after the US Court of Appeals vacates the injunction against Leqselvi's ...

Sun Pharma stock rose more than 5 per cent intraday on Friday, April 11, after the company got a favorable order from a US ...

Sun Pharma shares gained after a U.S. court lifted an injunction, clearing the way for the launch of LEQSELVI, its drug for ...